Preclinical study of the α₂-adrenostimulant Brimozolin (brimonidine)

A preclinical study of the α₂ -adrenostimulant Brimozolin (brimonidine tartrate), synthesized by an original method at OAO Center for the Chemistry of Therapeutic Agents_All-Russian Chemico-Pharmaceutical Research Institute (TsKhLS-VNIKhFI), was performed using 29 rabbits. Brimozolin eye drops decre...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical chemistry journal Vol. 43; no. 7; pp. 375 - 377
Main Authors Ermakova, V. N, Zakharova, G. P, Rybko, G. V
Format Journal Article
LanguageEnglish
Published Boston Boston : Springer US 01.07.2009
Springer US
Subjects
chronic toxicity
histological studies
hydrodynamic parameters
intraocular pressure
Medicine
Molecular-Biological Problems of Drug Design and Mechanisms of Drug Action
Organic Chemistry
Pharmacology/Toxicology
Pharmacy
Specific activity
Specific activity
hydrodynamic parameters
histological studies
intraocular pressure
chronic toxicity
Online AccessGet full text

Cover

More Information
Summary:A preclinical study of the α₂ -adrenostimulant Brimozolin (brimonidine tartrate), synthesized by an original method at OAO Center for the Chemistry of Therapeutic Agents_All-Russian Chemico-Pharmaceutical Research Institute (TsKhLS-VNIKhFI), was performed using 29 rabbits. Brimozolin eye drops decreased intraocular pressure in the intact eyes of experimental animals by 3 - 5 mmHg for one day by producing significant increases in the outflow of aqueous humor and suppressing its production. Histological studies of the outer and inner layers of the eye showed that there were no changes. This agent is recommended for clinical trials.
Bibliography:http://dx.doi.org/10.1007/s11094-009-0320-1
ISSN:0091-150X
1573-9031
DOI:10.1007/s11094-009-0320-1